When it launched in February of 2015, Meerkat looked like it was going to be the hottest social application since Facebook. Two years later, Meerkat’s live-streaming platform is gone, taken down in the fall of 2016 after losing a battle for users with the similar (but Twitter-backed) platform Periscope. But although the players have changed, interest in live streaming has stuck around – and in some cases, grown quickly as users see the possibilities for it and existing social platforms begin adding it to their arsenal of features.

Shares of Arrowhead Pharmaceuticals Inc. sank one day after the company said it would stop developing all drugs being tested on humans.

A widely prescribed diabetes drug failed to reduce deaths or rehospitalizations in a study of patients with advanced heart failure.

Timely use of Novartis’ Entresto could prevent or postpone over 28,000 US deaths per year   EAST HANOVER, N.J., June 22, 2016 /PRNewswire/ — A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or […]

Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.

Novartis’s heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.

New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine.

Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment was a cost-effective option.   Entresto has a list price of 1,194 pounds ($1,809) a year in Britain, or less than half the price of […]

Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years. The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — […]

The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.   Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate […]